Improving adherence with high-intensity lipid lowering therapies could greatly reduce CVD risk.
Researchers conducted a meta-analysis of data from all large statin trials to especially compare the effects of statin therapy on persons older than age 75.
Researchers evaluated the prevalence of elevated triglyceride levels in adults with and without statin use and the related 10-year predicted risk for atherosclerotic cardiovascular disease.
Compared with men, women who have diabetes experience greater changes in the cumulative burden of cardiovascular risk factors from young to middle-age adulthood.
Researchers examined whether lipoprotein(a) cholesterol life-years can effectively measure cumulative risk for atherosclerotic cardiovascular disease and questioned whether this metric may apply to the incidence of aortic valve calcification.
Investigators sought to determine the effect HDL-C subparticles HDL2-C and HDL3-C have on assessing CAD severity in patients who receive statin therapy.
Patients with plaque psoriasis have a reduced health-related quality of life, mainly in terms of emotional aspects.
Investigators evaluated the effect of linagliptin vs placebo on cardiovascular and kidney disease outcomes in patients with T2D at high risk for cardiovascular and renal events.
PCSK9 inhibitors are a potentially safe lipid-lowering therapy for heart transplant recipients with suboptimal LDL management on statins.
Population-level data can help medical practitioners use electronic health records to identify patients at risk for cardiovascular disease.
Patients using a high-intensity statin after a STEMI experienced a significant increase in minimum fibrous cap thickness.